The Renin-Angiotensin-Aldosterone System and Blood Pressure Regulation
The RAAS is the primary hormonal cascade controlling arterial blood pressure through coordinated mechanisms of vasoconstriction, sodium retention, and fluid volume expansion, making it the central therapeutic target for hypertension management. 1
Core Physiological Mechanisms
The RAAS cascade activates through three specific triggers that signal the need for blood pressure elevation 1:
- Decreased blood pressure detected by renal baroreceptors 1
- Reduced sodium chloride delivery to the macula densa of the distal convoluted tubule 1
- Sympathetic nervous system stimulation of renal nerves 1
The Cascade Sequence
Renin secretion initiates the cascade by cleaving angiotensinogen (produced by the liver) to form angiotensin I 2. This represents the rate-limiting step that determines overall system activity 2.
Angiotensin-converting enzyme (ACE) then converts angiotensin I to angiotensin II, the principal effector molecule 3, 4. This conversion occurs primarily in pulmonary vascular endothelium but also in tissue beds throughout the body 2.
Angiotensin II: The Primary Pressor Agent
Angiotensin II elevates blood pressure through six distinct mechanisms 1:
- Systemic arteriolar vasoconstriction via AT1 receptor activation on vascular smooth muscle 3, 4
- Increased sodium reabsorption in the proximal convoluted tubule 1
- Sympathetic nervous system activation amplifying vasoconstriction 1
- Stimulation of thirst increasing fluid intake 1
- Aldosterone release from the adrenal cortex 1, 3
- Antidiuretic hormone (ADH) secretion from the posterior pituitary 1
Aldosterone's Role in Volume Expansion
Aldosterone directly stimulates renal sodium and fluid retention to increase blood volume, representing the final common pathway for sustained blood pressure elevation 1. This mineralocorticoid acts on the distal nephron to enhance sodium reabsorption in exchange for potassium and hydrogen ion secretion 3, 4.
Receptor Specificity and Therapeutic Implications
The AT1 receptor mediates virtually all detrimental cardiovascular effects of angiotensin II 3, 4. Valsartan demonstrates 20,000-fold greater affinity for AT1 versus AT2 receptors, while losartan shows approximately 1,000-fold selectivity 3, 4. The AT2 receptor's role in cardiovascular homeostasis remains unclear, though it may provide counter-regulatory vasodilation 3.
A critical pitfall: ACE inhibitors block bradykinin degradation (causing cough in 10-20% of patients), while angiotensin receptor blockers do not affect bradykinin metabolism, explaining their superior tolerability profile 3, 4.
Feedback Regulation and Compensatory Mechanisms
Angiotensin II normally suppresses renin secretion through negative feedback 3, 4. When RAAS blockers interrupt this feedback loop, plasma renin activity increases 2-3 fold, with consequent rises in angiotensin II levels 3, 4. However, these compensatory increases do not overcome the antihypertensive effects of receptor blockade at therapeutic doses 3.
Pathophysiological Consequences of RAAS Overactivation
Beyond blood pressure elevation, chronic RAAS activation drives end-organ damage through 5:
- Oxidative stress generation in vascular endothelium 5
- Chronic inflammation with inflammatory marker elevation 5
- Fibrotic remodeling of heart, kidneys, and blood vessels 5
- Glomerular capillary hypertension causing progressive nephropathy 6
The American Heart Association recognizes that RAAS dysregulation plays a critical role in hypertensive disorders of pregnancy, including preeclampsia, through altered placental development and maternal vascular dysfunction 7.
Therapeutic Targeting of the RAAS
RAAS inhibitors represent cornerstone treatments for hypertension, heart failure, coronary disease, and chronic kidney disease 8. The European Heart Journal recommends initiating at low doses and titrating to maximum tolerated evidence-based doses to achieve mortality reduction 8.
The primary therapeutic classes include 8:
- ACE inhibitors (first-line for most patients)
- Angiotensin receptor blockers (when ACE inhibitors cause cough)
- Mineralocorticoid receptor antagonists (added for resistant hypertension)
- Direct renin inhibitors (limited role due to side effects) 9
Critical contraindication: All RAAS inhibitors are absolutely contraindicated during pregnancy due to fetal renal dysgenesis, oligohydramnios, and death 8. Women of childbearing potential require counseling before initiation.
Monitoring Requirements
When initiating or up-titrating RAAS inhibitors, monitor 8:
- Serum creatinine at 1-2 weeks (acceptable increase up to 30% from baseline) 8
- Serum potassium at 1-2 weeks (target <5.5 mEq/L) 8
- Blood pressure response at 2-4 weeks 3, 4
For bilateral renal artery stenosis, the American Heart Association advises extreme caution with RAAS inhibitors due to risk of acute renal failure from loss of angiotensin II-mediated efferent arteriolar tone 8.
Managing Hyperkalemia Without Discontinuing Therapy
For potassium 5.0-5.5 mEq/L, the European Heart Journal recommends continuing RAAS inhibitors while implementing 8:
- Dietary potassium restriction to <2-3 grams daily 8
- Loop or thiazide diuretics to enhance renal potassium excretion 8
- Newer potassium binders (patiromer, sodium zirconium cyclosilicate) to maintain therapy 8
Discontinuing RAAS inhibitors for mild hyperkalemia increases cardiovascular events, hospitalizations, and mortality, making potassium management strategies preferable to drug cessation 8.